 | |
| Abbreviation | NCATS |
|---|---|
| Formation | December 23, 2011 |
| Type | U.S. government agency |
| Legal status | Active |
| Headquarters | Bethesda, Maryland, US |
Director | Joni L. Rutter |
Parent organization | National Institutes of Health |
| Affiliations | United States Public Health Service |
| Website | ncats |
The National Center for Advancing Translational Sciences (NCATS) was established on December 23, 2011[1] and is located in Bethesda, Maryland. NCATS is one of 27 institutes and centers of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The mission of NCATS is to transform scientific discoveries into new treatments and cures for disease that can be delivered faster to patients. The budget provided to NCATS for fiscal year 2018 is $557,373,000.[2]
NCATS was created on December 23, 2011 by the Consolidated Appropriations Act, 2012.[3]
The center was created from a number of existing NIH programs:[4]
Past directors 2011 – present[7]
| Portrait | Director | Took office | Left office |
|---|---|---|---|
|
Thomas R. Insel (acting) | December 23, 2011 | September 22, 2012 |
|
Christopher P. Austin | September 23, 2012 | April 15, 2021 |
|
Joni L. Rutter | April 16, 2021 | Present |
NCATS is organized into a number of divisions:
The stated goal of NCATS is to promote research in both existing and new areas of medicine and science, in order to promote public health and to overcome high failure rates in clinical trials.[9][10] To accomplish this, NCATS supports 31 programs and initiatives that relate to translational research and improving the speed of therapeutic development.[11] The 31 programs and initiatives involve a range of STEM-related fields including biology, biochemistry, chemistry, bioengineering, virology, genetics, and data science.[12] Within the realm of translational science, issues that NCATS is particularly focused on addressing using its programs, initiatives, and partnerships include increasing the success and de-risking the costs associated with therapeutic development, incentivizing more collaborative work, and addressing data transparency issues.[13]
During the COVID-19 pandemic, NCATS launched an open data initiative to promote collaborative sharing of COVID-related drug data.[14] An additional data sharing partnership with several other government institutes resulted in a study detailing the COVID-related risks for patients with chronic obstructive pulmonary disease.[15][16]
| International |
|
|---|---|
| National |
|
